Zhipu AI Launches GLM-Image Model Trained on Huawei Chips, Boosting China’s AI Self-Reliance Drive 
Federal Judge Clears Way for Jury Trial in Elon Musk’s Fraud Lawsuit Against OpenAI and Microsoft 
Jamie Dimon Signals Possible Five More Years as JPMorgan CEO Amid Ongoing Succession Speculation 
Boeing Reaches Tentative Settlement With Canadian Victim’s Family in 737 MAX Crash Lawsuits 
U.S. Lawmakers Raise Alarm Over Trump Approval of Nvidia AI Chip Sales to China 
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio 
Toyota Industries Buyout Faces Resistance as Elliott Rejects Higher Offer 
Chevron Set to Expand Venezuela Operations as U.S. Signals Shift on Oil Sanctions 
BlueScope Steel Announces A$1 Special Dividend After Asset Sales 
Alphabet Stock Poised for Growth as Bank of America Sees Strong AI Momentum Into 2026 
TSMC Set to Post Record Q4 Profit as AI Chip Demand Accelerates 
TSMC Shares Hit Record High as AI Chip Demand Fuels Strong Q4 Earnings 
Amazon Reviews Supplier Costs as U.S.–China Tariffs Ease 
Boeing Reaches Tentative Labor Deal With SPEEA Workers After Spirit AeroSystems Acquisition 
BYD Shares Rise in Hong Kong on Reports of Battery Supply Talks With Ford 
Netflix Plans All-Cash Bid for Warner Bros Discovery Studios Amid Intense Hollywood Takeover Battle 
One Percent Rule Checklist For Safer Forex Trading Risk 
NEW YORK and MELBOURNE, Australia, April 06, 2017 -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced that it has received A$3.7 million from the Australian Government for Research & Development (R&D) activities conducted during the 2016 financial year. The funds were provided to Mesoblast under the Government's R&D Tax Incentive Program, which is designed to support industry innovation.
About Mesoblast
Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) is a global leader in developing innovative cell-based medicines. The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a broad portfolio of late-stage product candidates. Mesoblast’s allogeneic, ‘off-the-shelf’ cell product candidates target advanced stages of diseases with high, unmet medical needs including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncologic/hematologic conditions.
Forward-Looking Statements
This press release includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblast's actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.
For further information, please contact: CORPORATE COMMUNICATIONS Julie Meldrum T: +61 3 9639 6036 E: [email protected] INVESTOR RELATIONS Schond Greenway T: +1 212 880 2060 E: [email protected]
